Skip to main content

Research Repository

Advanced Search

Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical ?-Blockers

Baker, Jillian G.; Fromont, Christophe; Bruder, Marjorie; Thompson, Kevin S.J.; Kellam, Barrie; Hill, Stephen J.; Gardiner, Sheila M.; Fischer, Peter M.

Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical ?-Blockers Thumbnail


Authors

JILLIAN BAKER jillian.baker@nottingham.ac.uk
Professor of Drug Discovery and Respiratory Medicine

Christophe Fromont

Marjorie Bruder

Kevin S.J. Thompson

Profile Image

BARRIE KELLAM BARRIE.KELLAM@NOTTINGHAM.AC.UK
Professor of Medicinal Chemistry

STEPHEN HILL STEVE.HILL@NOTTINGHAM.AC.UK
Professor of Molecular Pharmacology

Sheila M. Gardiner

Peter M. Fischer



Abstract

© 2020 American Chemical Society. For disorders of the skin, eyes, ears, and respiratory tract, topical drugs, delivered directly to the target organ, are a therapeutic option. Compared with systemic oral therapy, the benefits of topical treatments include a faster onset of action, circumventing the liver first pass drug metabolism, and reducing systemic side effects. Nevertheless, some systemic absorption still occurs for many topical agents resulting in systemic side effects. One way to prevent these would be to develop drugs that are instantly degraded upon entry into the bloodstream by serum esterases. Because topical β-blockers are used in glaucoma and infantile hemeangioma and cause systemic side effects, the β-adrenoceptor system was used to test this hypothesis. Purified liver esterase reduced the apparent affinity of esmolol, an ester-containing β-blocker used in clinical emergencies, for the human β-adrenoceptors in a concentration and time-dependent manner. However, purified serum esterase had no effect on esmolol. Novel ester-containing β-blockers were synthesized and several were sensitive to both liver and serum esterases. Despite good in vitro affinity, one such compound, methyl 2-(3-chloro-4-(3-((2-(3-(3-chlorophenyl)ureido)ethyl)amino)-2-hydroxypropoxy)phenyl)acetate, had no effect on heart rate when injected intravenously into rats, even at 10 times the equipotent dose of esmolol and betaxolol that caused short and sustained reductions in heart rate, respectively. Thus, ester-based drugs, sensitive to serum esterases, offer a mechanism for developing topical agents that are truly devoid of systemic side effects. Furthermore, differential susceptibility to liver and serum esterases degradation may also allow the duration of systemic availability for other drugs to be fine-tuned.

Citation

Baker, J. G., Fromont, C., Bruder, M., Thompson, K. S., Kellam, B., Hill, S. J., …Fischer, P. M. (2020). Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers. ACS Pharmacology & Translational Science, 3(4), 737-748. https://doi.org/10.1021/acsptsci.0c00051

Journal Article Type Article
Acceptance Date Jul 1, 2020
Online Publication Date Jul 23, 2020
Publication Date Aug 14, 2020
Deposit Date Jul 2, 2020
Publicly Available Date Mar 29, 2024
Journal ACS Pharmacology and Translational Science
Electronic ISSN 2575-9108
Publisher American Chemical Society
Peer Reviewed Peer Reviewed
Volume 3
Issue 4
Pages 737-748
DOI https://doi.org/10.1021/acsptsci.0c00051
Public URL https://nottingham-repository.worktribe.com/output/4745008
Publisher URL https://pubs.acs.org/doi/10.1021/acsptsci.0c00051
Additional Information This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Pharmacology & Translational Science, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/10.1021/acsptsci.0c00051

Files





You might also like



Downloadable Citations